However, autoimmune markers are the main therapeutic targets in all these approaches; although the idea has been hypothesized, there is little proof (either experimental or clinical) that Cat S inhibitors have the direct ability to reverse the vascular and muscular changes in SLE associated with PAH. Here, CAT is linked to pulmonary arterial hypertension.